| # | Drug | Count |
|---|---|---|
| 0 | CETUXIMAB | 213 |
| 1 | CISPLATIN | 129 |
| 2 | CAPECITABINE | 113 |
| 3 | DOCETAXEL | 99 |
| 4 | DOCETAXEL ANHYDROUS | 99 |
| 5 | CARBOPLATIN | 94 |
| 6 | FLUOROURACIL | 87 |
| 7 | FLUOROURACIL CREAM, 0.5% | 87 |
| 8 | TRASTUZUMAB | 81 |
| 9 | PACLITAXEL | 76 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | AMIFOSTINE | 16 | 0.0198 |
| 1 | CAPSICUM ANNUUM, CETRARIA ISLANDICA, FUCUS VESICULOSUS, GLANDULA SUPRARENALIS SUIS, THYROIDINUM (SUIS), CADMIUM IODATUM, HYDRANGEA ARBORESCENS, PHOSPHORICUM ACIDUM, PHOSPHORUS, PULSATILLA (PRATENSIS), STRONTIUM CARBONICUM, URANIUM NITRICUM, X-RAY | 13 | 0.0127 |
| 2 | MITOMYCIN | 28 | 0.0077 |
| 3 | CETUXIMAB | 213 | 0.0067 |
| 4 | ADO-TRASTUZUMAB EMTANSINE | 22 | 0.0026 |
| 5 | VEMURAFENIB | 30 | 0.0025 |
| 6 | PERTUZUMAB | 57 | 0.0021 |
| 7 | CISPLATIN | 129 | 0.0016 |
| 8 | APREPITANT | 11 | 0.0015 |
| 9 | DOCETAXEL | 99 | 0.0015 |
| # | Drug class | Count |
|---|---|---|
| 0 | Platinum-based Drug [EPC] | 252 |
| 1 | Epidermal Growth Factor Receptor Antagonist [EPC] | 222 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 194 |
| 3 | Microtubule Inhibitor [EPC] | 169 |
| 4 | Alkylating Drug [EPC] | 96 |
| 5 | Corticosteroid [EPC] | 93 |
| 6 | HER2/neu Receptor Antagonist [EPC] | 91 |
| 7 | Kinase Inhibitor [EPC] | 89 |
| 8 | Aromatase Inhibitor [EPC] | 86 |
| 9 | Nonsteroidal Anti-inflammatory Drug [EPC] | 60 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Epidermal Growth Factor Receptor Antagonist [EPC] | 222 | 0.0047 |
| 1 | Actinomycin [EPC] | 5 | 0.0023 |
| 2 | Benzodiazepine Antagonist [EPC] | 2 | 0.0023 |
| 3 | Guanylate Cyclase-C Agonist [EPC] | 4 | 0.0019 |
| 4 | Endoglycosidase [EPC] | 3 | 0.0016 |
| 5 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 11 | 0.0013 |
| 6 | HER2/neu Receptor Antagonist [EPC] | 91 | 0.0012 |
| 7 | Microtubule Inhibitor [EPC] | 169 | 0.0010 |
| 8 | Sulfonamide Antibacterial [EPC] | 4 | 0.0010 |
| 9 | Platinum-based Drug [EPC] | 252 | 0.0009 |